A DeSoto subsidiary of a company that developed and sells a test for the early detection of lung cancer has been acquired.
HDL Inc., which is based in Richmond, Va., bought most of the assets of Oncimmune USA LLC, which has 25 employees and is based in DeSoto, where it will continue to be situated.
The financial terms of the deal were not disclosed. The purchase includes a licensing agreement with Oncimmune USA’s parent company for the exclusive U.S. rights to a simple physician-ordered blood test for lung cancer. The DeSoto facility is a lab that does the tests.
HDL, which has 756 employees, is known as a high-growth company that has made a name in testing for cardiovascular diseases. Doing the same for lung cancer is a step in offering a future menu of cancer tests.
“Since the beginnings of Health Diagnostic Laboratory five years ago, we have always said that our model of early detection and prevention for cardiovascular disease is a platform to do the same with other disease and chronic conditions, and this agreement with Oncimmune pushes us deeper into that mission by expanding our focus to include lung cancer,” said Tonya Mallory, HDL’s president and chief executive.
Oncimmune USA has been a subsidiary of Oncimmune Ltd., based in the United Kingdom. The company launched its early cancer detection test, named EarlyCDT, in 2009. The EarlyCDT for lung cancer is the company’s first approved test. A test for a type of liver cancer is in the early stages of validation.